lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval

Phase 3

Ipsen Biopharmaceuticals, Inc. (IPSEY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

5 competitors in Acromegaly

Drug Information

Target Indication

Acromegaly

Clinical Trial

NCT00444873

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

IPSEY

Ipsen Biopharmaceuticals, Inc.

Healthcare•North America•NASDAQ

Related Pipeline

Triptorelin pamoate (embonate) saltPhase 3

Advanced Prostate Cancer

Lanreotide (Autogel formulation)Phase 3

Acromegaly

OdevixibatPhase 3

Biliary Atresia

Lanreotide Autogel®Phase 3

Acromegaly

ElafibranorPhase 3

Primary Biliary Cholangitis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts